Mycobacterial Lung Diseases in Virginia: Sequencing and Clinical Determinants of Relapse and Outcome

Inclusion Criteria:

• All subjects:

  • Race/ethnicity: any
  • Subject has no history of active Tuberculosis in the last 2 years.
  • NTM culture positive from respiratory specimen (sputum or bronchial lavage fluid)
  • Subject must have an available sputum sample that was taken in the last 2 years. If a sample is not available, the subject must be willing and able to provide a sputum sample.

  • Meets the following Infectious Diseases Society of America (IDSA) criteria for NTM lung disease:

    • 2 or more sputum (or 1 bronchoscopy/biopsy) cultures positive for "Mycobacterium Avium Complex" or "Mycobacterium abscessus) within the last 2 years.
    • Nodules, cavities, and/or bronchiectasis on CT scan within the past 2 years
    • If if the above data are not available, but a patient's Infectious Disease or Pulmonary physician has documented the diagnosis of NTM lung disease in their notes, this will suffice

PK subjects:

• Newly diagnosed with NTM lung disease and beginning antibiotics for NTM within the last 3 months from enrollment.
• Prior diagnosis of NTM lung disease, and starting initial therapy within the last 3 months prior to enrollment.
• Consent to pharmacokinetic testing within one month of enrollment and at six months of therapy

Exclusion Criteria:

• List the criteria for exclusion

All subjects:

• Age < 18 years
• Subject has cystic fibrosis or other inherited disorders of airway ciliary dysfunction (eg, primary ciliary dyskinesia)
• Unable to participate in follow-up requirements by phone or clinic visit

PK subjects:

• Unable to have blood drawn for pharmacokinetic testing